NASDAQ:VERU
Veru Stock News
$1.33
-0.0400 (-2.92%)
At Close: May 10, 2024
Veru updates Phase 1b/2 data for sabizabulin in prostate cancer
02:25pm, Thursday, 17'th Feb 2022 Seeking Alpha
Veru (VERU) highlighted the long-term efficacy of its experimental cancer therapy, sabizabulin, after announcing the additional data from its Phase 1b/2 clinical study in…
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
01:30pm, Thursday, 17'th Feb 2022 GlobeNewswire Inc.
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,
Warning: VERU is at high risk of performing badly
09:59am, Tuesday, 15'th Feb 2022 Seeking AlphaVeru to further advance late-stage trial for COVID-19 therapy after data analysis
06:06pm, Monday, 14'th Feb 2022 Seeking Alpha
Veru <> announced on Monday that an independent panel recommended the continuation of its global Phase 3 COVID-19 registration study for oral sabizabulin as previously…
Data Committee Recommends Veru''s COVID-19 Trial To Continue Unmodified
03:13pm, Monday, 14'th Feb 2022 Benzinga
The Independent Data Monitoring Committee (IDMC) has conducted a planned conditional power analysis of the first 75 randomized patients in Veru Inc''s (NASDAQ: VERU ) Phase 3 trial of sabizabulin. The trial included hospitalized patients with moderate to severe COVID-19 infection at high risk for acute respiratory distress syndrome … Full story available on Benzinga.com
Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
01:30pm, Monday, 14'th Feb 2022 GlobeNewswire Inc.
--Planned Conditional Statistical Power Analysis was Conducted—
Veru Inc. (VERU) CEO Mitchell Steiner on Q1 2022 Results - Earnings Call Transcript
07:26pm, Wednesday, 09'th Feb 2022 Seeking AlphaVeru Inc. (VERU) CEO Mitchell Steiner on Q1 2022 Results - Earnings Call Transcript
02:26pm, Wednesday, 09'th Feb 2022
Veru Inc. (VERU) CEO Mitchell Steiner on Q1 2022 Results - Earnings Call Transcript
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
01:31pm, Wednesday, 09'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab
Humanigen,
Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates
12:45pm, Wednesday, 09'th Feb 2022 Zacks Investment Research
Veru Inc. (VERU) delivered earnings and revenue surprises of 27.27% and 17.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%
11:30am, Wednesday, 09'th Feb 2022 GlobeNewswire Inc.
--FC2 Prescription Business Entering 6th Year of Growth -- --FDA Approves Company’s ENTADFI™, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway--
Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%
11:30am, Wednesday, 09'th Feb 2022 GlobeNewswire
--FC2 Prescription Business Entering 6 th Year of Growth -- --FDA Approves Company’s ENTADFI™, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway--
Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates
09:13am, Wednesday, 09'th Feb 2022
Veru Inc. (VERU) delivered earnings and revenue surprises of 27.27% and 17.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Scheduled For February 9, 2022
09:02am, Wednesday, 09'th Feb 2022 Benzinga
Companies Reporting Before The Bell Equinor (NYSE: EQNR ) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion. ICL Group (NYSE: ICL ) is expected to report quarterly earnings at $0.13 per share on revenue of $1.82 billion. Madison Square Garden (NYSE: MSGE ) is projected to report quarterly earnings at $1.00 per share on revenue of $538.98 million. Anavex Life Sciences (NASDAQ: AVXL ) is likely to report earnings for its first quarter. Orion Energy Sys (NASDAQ: OESX ) is likely to report quarterly earnings at $0.04 per share on revenue of $32.86 million. Penske Automotive Group (NYSE: PAG ) is estimated to report quarterly earnings at $3.69 per share on revenue of $6.22 billion. Mastech Digital (AMEX: MHH ) is projected to report quarterly earnings at $0.38 per share on revenue of $59.90 million. Perion Network (NASDAQ: PERI ) is projected to report quarterly earnings at $0.39 per share on revenue of $144.96 million. Ares Capital (NASDAQ: ARCC ) is estimated to report quarterly earnings at $0.49 per share on revenue of $459.14 million. Lithia Motors (NYSE: LAD ) is expected to report quarterly earnings at $10.14 per share on revenue of $6.15 billion. Cameco (NYSE: CCJ ) is expected to report quarterly earnings at $0.03 per share on revenue of $362.39 million. CDW (NASDAQ: CDW ) is expected to report quarterly earnings at $1.92 per share on revenue of $5.18 billion. Bunge (NYSE: BG ) is projected to report quarterly earnings at $2.55 per share on revenue of $13.61 billion. Yum Brands (NYSE: YUM ) is likely to report quarterly earnings at $1.09 per share on revenue of $1.88 billion. Crown Crafts (NASDAQ: CRWS ) is likely to report quarterly earnings at $0.24 per share on revenue of $18.80 million.
Veru FQ1 2022 Earnings Preview
06:16pm, Tuesday, 08'th Feb 2022 Seeking Alpha
Veru (NASDAQ:VERU) is scheduled to announce FQ1 earnings results on Wednesday, February 9th, before market open.The consensus EPS Estimate is -$0.07 vs